{"id":"NCT01602562","sponsor":"GlaxoSmithKline","briefTitle":"Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients","officialTitle":"A Multicenter, Open-label Study to Evaluate Preventive Efficacy for Herpes Simplex Virus Infection and Safety of 256U87 (Valaciclovir Hydrochloride) in Adult and Pediatric Hematopoietic Stem Cell Transplantation Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05-07","primaryCompletion":"2013-05-01","completion":"2013-05-24","firstPosted":"2012-05-21","resultsPosted":"2014-02-24","lastUpdate":"2018-08-17"},"enrollment":40,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Simplex"],"interventions":[{"type":"DRUG","name":"VACV tablets (Adults or pediatrics) or granules (pediatrics)","otherNames":["256U87 tablet or granule"]}],"arms":[{"label":"VACV (256U87; valaciclovir hydrochloride)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the preventive efficacy for HSV infection and safety of valaciclovir (VACV) in the adult and pediatric HSCT patients.","primaryOutcome":{"measure":"Number of Participants With a Herpes Simplex Virus (HSV) Infection","timeFrame":"From Day -7 (7 days before HSCT) to Day 35 (35 days after HSCT)","effectByArm":[{"arm":"Adult Participants: VACV 500 mg Tablet","deltaMin":0,"sd":null},{"arm":"Pediatric Participants: VACV 500 mg Granules/Tablets","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG001","p":null}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":11,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":21},"commonTop":["Diarrhoea","Decreased appetite","Nausea","Vomiting","Thrombocytopenia"]}}